Denali Therapeutics Inc. (DNLI) Operating Income (Loss) USD 2017 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Denali Therapeutics Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2017 to 2024.
  • Denali Therapeutics Inc. Operating Income (Loss) for the quarter ending March 31, 2024 was -$118 M, a 2.57% increase year-over-year.
  • Denali Therapeutics Inc. Operating Income (Loss) for the twelve months ending March 31, 2024 was -$194 M, a 51% increase year-over-year.
  • Denali Therapeutics Inc. annual Operating Income (Loss) for 2023 was -$197 M, a 42.3% increase from 2022.
  • Denali Therapeutics Inc. annual Operating Income (Loss) for 2022 was -$341 M, a 15.2% decline from 2021.
  • Denali Therapeutics Inc. annual Operating Income (Loss) for 2021 was -$296 M, a 572% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$194 M -$118 M +$3.1 M +2.57% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 -$197 M -$133 M -$27.2 M -25.8% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 -$169 M -$114 M -$6.31 M -5.87% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-07
Q2 2023 -$163 M $170 M +$232 M Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-08
Q1 2023 -$395 M -$121 M -$54.3 M -81.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 -$341 M -$105 M -$28.2 M -36.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 -$313 M -$107 M -$21.9 M -25.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 -$291 M -$61.4 M +$401 K +0.65% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$291 M -$66.5 M +$4.72 M +6.63% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 -$296 M -$77.1 M -$321 M -132% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 $25.4 M -$85.6 M -$25.5 M -42.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $50.9 M -$61.8 M -$540 K -0.88% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $51.5 M -$71.2 M -$11.3 M -18.8% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $62.7 M $244 M +$302 M Oct 1, 2020 Dec 31, 2020 10-K 2023-02-27
Q3 2020 -$239 M -$60.1 M -$9.96 M -19.9% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$229 M -$61.3 M +$1.49 M +2.37% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 -$231 M -$60 M -$17.5 M -41.1% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 -$213 M -$57.8 M -$132 M -177% Oct 1, 2019 Dec 31, 2019 10-K 2020-02-27
Q3 2019 -$80.7 M -$50.2 M -$12.2 M -32.1% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$68.5 M -$62.8 M -$5.38 M -9.38% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-07
Q1 2019 -$63.1 M -$42.5 M -$16.8 M -65.1% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$46.4 M $74.7 M +$98.3 M Oct 1, 2018 Dec 31, 2018 10-K 2020-02-27
Q3 2018 -$145 M -$38 M -$15.7 M -70.3% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-27
Q2 2018 -$129 M -$57.4 M -$34.8 M -154% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-27
Q1 2018 -$94.1 M -$25.7 M -$4 M -18.4% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-27
Q4 2017 -$90.1 M -$23.5 M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-12
Q3 2017 -$22.3 M Jul 1, 2017 Sep 30, 2017 10-K 2019-03-12
Q2 2017 -$22.6 M Apr 1, 2017 Jun 30, 2017 10-K 2019-03-12
Q1 2017 -$21.7 M Jan 1, 2017 Mar 31, 2017 10-K 2019-03-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.